Compare Stocks: HRTX, SUPN, PRLD, ADCT, and HRMY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.07 -0.5%	$1.17	$0.78 ▼ $4.98	$135.97M	1.84	1.81 million shs	989,097 shs
HRMY Harmony Biosciences	$41.52	$38.12	$25.52 ▼ $43.49	$2.42B	0.93	744,645 shs	1.12 million shs
HRTX Heron Therapeutics	$0.32	$0.40	$0.30 ▼ $1.58	$59.90M	1.61	2.01 million shs	1.37 million shs
PRLD Prelude Therapeutics	$4.59	$5.06	$0.98 ▼ $6.83	$366.28M	0.97	533,136 shs	520,337 shs
SUPN Supernus Pharmaceuticals	$41.64	$46.18	$41.11 ▼ $59.68	$2.42B	0.56	539,175 shs	707,159 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-21.69%	+5.97%	0.00%	-67.82%
HRMY Harmony Biosciences	0.00%	-1.73%	+8.92%	+21.47%	+28.19%
HRTX Heron Therapeutics	0.00%	-8.26%	-6.30%	-21.93%	-74.96%
PRLD Prelude Therapeutics	0.00%	-15.93%	-17.30%	+2.91%	+306.19%
SUPN Supernus Pharmaceuticals	0.00%	-4.34%	-13.74%	-5.06%	-8.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.07 -0.5%	$1.17	$0.78 ▼ $4.98	$135.97M	1.84	1.81 million shs	989,097 shs
HRMY Harmony Biosciences	$41.52	$38.12	$25.52 ▼ $43.49	$2.42B	0.93	744,645 shs	1.12 million shs
HRTX Heron Therapeutics	$0.32	$0.40	$0.30 ▼ $1.58	$59.90M	1.61	2.01 million shs	1.37 million shs
PRLD Prelude Therapeutics	$4.59	$5.06	$0.98 ▼ $6.83	$366.28M	0.97	533,136 shs	520,337 shs
SUPN Supernus Pharmaceuticals	$41.64	$46.18	$41.11 ▼ $59.68	$2.42B	0.56	539,175 shs	707,159 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-21.69%	+5.97%	0.00%	-67.82%
HRMY Harmony Biosciences	0.00%	-1.73%	+8.92%	+21.47%	+28.19%
HRTX Heron Therapeutics	0.00%	-8.26%	-6.30%	-21.93%	-74.96%
PRLD Prelude Therapeutics	0.00%	-15.93%	-17.30%	+2.91%	+306.19%
SUPN Supernus Pharmaceuticals	0.00%	-4.34%	-13.74%	-5.06%	-8.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	369.48% Upside
HRMY Harmony Biosciences	2.36	Hold	$47.11	13.47% Upside
HRTX Heron Therapeutics	2.00	Hold	$2.00	533.91% Upside
PRLD Prelude Therapeutics	2.40	Hold	$7.67	67.03% Upside
SUPN Supernus Pharmaceuticals	2.43	Hold	$62.83	50.90% Upside

Current Analyst Ratings Breakdown

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/26/2026	HRMY Harmony Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
8/17/2026	HRMY Harmony Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/11/2026	HRMY Harmony Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/5/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$39.00
8/5/2026	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$29.00 ➝ $34.00
8/5/2026	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$37.00
8/4/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$70.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.67	N/A	N/A	($1.50) per share	-0.71
HRMY Harmony Biosciences	$868.45M	2.78	$3.18 per share	13.06	$15.11 per share	2.75
HRTX Heron Therapeutics	$154.90M	0.39	N/A	N/A	$0.07 per share	4.51
PRLD Prelude Therapeutics	$12.14M	30.17	N/A	N/A	$1.09 per share	4.21
SUPN Supernus Pharmaceuticals	$718.95M	3.37	$3.78 per share	11.03	$18.52 per share	2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
HRMY Harmony Biosciences	$158.69M	$3.08	13.48	10.43	0.38	18.88%	20.06%	14.15%	11/3/2026 (Estimated)
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/3/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	10.79	0.77	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
HRMY Harmony Biosciences	0.13	3.48	3.45
HRTX Heron Therapeutics	24.35	2.49	1.51
PRLD Prelude Therapeutics	N/A	4.07	4.07
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
HRMY Harmony Biosciences	86.23%
HRTX Heron Therapeutics	80.01%
PRLD Prelude Therapeutics	79.72%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
HRMY Harmony Biosciences	11.00%
HRTX Heron Therapeutics	6.10%
PRLD Prelude Therapeutics	49.20%
SUPN Supernus Pharmaceuticals	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.67 million	121.16 million	Optionable
HRMY Harmony Biosciences	293	58.24 million	51.83 million	Optionable
HRTX Heron Therapeutics	300	189.85 million	178.27 million	Optionable
PRLD Prelude Therapeutics	120	79.80 million	40.54 million	Optionable
SUPN Supernus Pharmaceuticals	778	58.13 million	53.19 million	Optionable

HRTX, SUPN, PRLD, ADCT, and HRMY Headlines

Recent News About These Companies

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year Low - Time to Sell?

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Buys Shares of 23,254 Supernus Pharmaceuticals, Inc. $SUPN

September 6, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $1.30 Million in Supernus Pharmaceuticals, Inc. $SUPN

September 5, 2026 | marketbeat.com

Legal & General Group Plc Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

September 3, 2026 | marketbeat.com

Supernus Pharmaceuticals to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

Bank of New York Mellon Corp Makes New $17.55 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

September 1, 2026 | marketbeat.com

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

August 31, 2026 | globenewswire.com

156,422 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Man Group plc

August 30, 2026 | marketbeat.com

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Freestone Grove Partners LP Invests $14.72 Million in Supernus Pharmaceuticals, Inc. $SUPN

August 28, 2026 | marketbeat.com

91,070 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Algert Global LLC

August 28, 2026 | marketbeat.com

25,858 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by PDT Partners LLC

August 27, 2026 | marketbeat.com

Deutsche Bank AG Takes $2.96 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

August 27, 2026 | marketbeat.com

Elmind Capital LP Invests $3.26 Billion in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New $1.29 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

Quantbot Technologies LP Purchases Shares of 47,700 Supernus Pharmaceuticals, Inc. $SUPN

August 25, 2026 | marketbeat.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

August 24, 2026 | zacks.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Supernus Pharmaceuticals Inc

August 22, 2026 | money.usnews.com

NFJ Investment Group LLC Makes New $2.46 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

August 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, SUPN, PRLD, ADCT, and HRMY Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.06 -0.01 (-0.47%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$1.06 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Harmony Biosciences NASDAQ:HRMY

$41.52 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$41.67 +0.15 (+0.36%)

As of 09/11/2026 07:30 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Heron Therapeutics NASDAQ:HRTX

$0.32 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.32 +0.00 (+1.43%)

As of 09/11/2026 07:30 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Prelude Therapeutics NASDAQ:PRLD

$4.59 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.55 -0.04 (-0.96%)

As of 09/11/2026 07:57 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Supernus Pharmaceuticals NASDAQ:SUPN

$41.64 0.00 (0.00%)

As of 09/11/2026 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRTX, SUPN, PRLD, ADCT, and HRMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, SUPN, PRLD, ADCT, and HRMY Company Descriptions

ADC Therapeutics NYSE:ADCT

Harmony Biosciences NASDAQ:HRMY

Heron Therapeutics NASDAQ:HRTX

Prelude Therapeutics NASDAQ:PRLD

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRTX, SUPN, PRLD, ADCT, and HRMY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRTX, SUPN, PRLD, ADCT, and HRMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, SUPN, PRLD, ADCT, and HRMY Company Descriptions

ADC Therapeutics NYSE:ADCT

Harmony Biosciences NASDAQ:HRMY

Heron Therapeutics NASDAQ:HRTX

Prelude Therapeutics NASDAQ:PRLD

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools